Research Topics
| J S GlennSummaryAffiliation: Stanford University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A prenylation inhibitor prevents production of infectious hepatitis delta virus particlesBruno B Bordier
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 269 Campus Drive, Palo Alto, CA 94305-5187, USA
J Virol 76:10465-72. 2002..Farnesyltransferase inhibitors thus represent an attractive potential class of novel antiviral agents for use against HDV, including the genotypes associated with most severe disease...- Structural map of a microRNA-122: hepatitis C virus complexPhillip S Pang
Department of Medicinea and Protein and Nucleic Acid Facility, Stanford University School of Medicine, Stanford, California, USA
J Virol 86:1250-4. 2012..These additional interactions enhance HCV replication in cell culture. To our knowledge, this is the first biophysical study of this complex to reveal the importance of 'tail' miR-122 nucleotide interactions... 
Hepatitis dElif S Koytak
Jeffrey S Glenn, MD, PhD Division of Gastroenterology and Hepatology, CCSR Building, Room 3115A, Stanford University School of Medicine, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
Curr Treat Options Gastroenterol 10:456-63. 2007..The only approved therapy for chronic hepatitis D is interferon-alpha. Although transplantation offers a safe therapeutic option for managing end-stage HDV disease, novel therapeutic approaches are urgently needed...- Prenylation of HDAg and antiviral drug developmentJ S Glenn
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305 5187, USA
Curr Top Microbiol Immunol 307:133-49. 2006..These agents represent a new class of antiviral agents, with HDV as a first target. Here, a brief review of the HDV life cycle emphasizing the role of prenylation is presented along with implications for drug development and therapy... - Novel therapies for hepatitis C virus based on lessons from virologyJeffrey S Glenn
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305 5187, USA
Clin Gastroenterol Hepatol 3:S86-8. 2005..As a result, the way we treat HCV should change dramatically over the next few years... - Molecular virology of the hepatitis C virus: implication for novel therapiesJeffrey S Glenn
Division of Gastroenterology and Hepatology, Stanford University School of Medicine and Palo Alto Veterans Administration Medical Center, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
Clin Liver Dis 9:353-69, v. 2005..This should minimize the emergence of resistance against any single agent. The way we treat HCV should change dramatically over the next few years... - Use of a prenylation inhibitor as a novel antiviral agentJ S Glenn
Division of Gastroenterology, Stanford University School of Medicine and Veterans Administration Medical Center, Palo Alto, California 94305 5487, USA
J Virol 72:9303-6. 1998..These results demonstrate that the use of such a prenylation inhibitor-based antiviral therapy may be feasible and identify a novel class of potential antiviral agents... - An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replicationMenashe Elazar
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305-5187, USA
J Virol 78:11393-400. 2004..These results identify a key membrane-targeting domain which can form the basis for developing novel antiviral strategies... - Testing antivirals against hepatitis delta virus: farnesyl transferase inhibitorsBruno B Bordier
Division of Gastroenterology and Hepatology, Stanford University School of Medicine and Veterans Administration Medical Center, Palo Alto, CA, USA
Methods Mol Med 96:539-53. 2004 - Prenylation inhibitors: a novel class of antiviral agentsShirit Einav
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305-5187, USA
J Antimicrob Chemother 52:883-6. 2003.... - In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virusBruno B Bordier
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California 94305, USA
J Clin Invest 112:407-14. 2003..These results provide the first preclinical data supporting the in vivo efficacy of prenylation inhibition as a novel antiviral therapy with potential application to HDV and a wide variety of other viruses... - Overdependence on the host-an Achilles' heel of HCV?Jeffrey S Glenn
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA
Hepatology 39:1734-5. 2004 - TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replicationElla H Sklan
Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305 5187, USA
J Biol Chem 282:36354-61. 2007..These results highlight a novel mechanism by which viruses can hijack host cell machinery and suggest an attractive model whereby the NS5A-TBC1D20 interaction may promote viral membrane-associated RNA replication... - A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replicationElla H Sklan
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR 3115A, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
J Virol 81:11096-105. 2007..These results suggest that pharmacologic disruption of this NS5A-interacting partner can be contemplated as a potential new antiviral strategy against a pathogen affecting nearly 3% of the world's population... - Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranesNam Joon Cho
Department of Materials Science and Engineering, Stanford University, 381 North South Mall, Stauffer III, Stanford, CA 94305, USA
J Virol 81:6682-9. 2007..These results also demonstrate the successful development of a new nanosensor technology ideal both for studying the interaction between a protein and its target membrane and for developing inhibitors of that interaction... - Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replicationMenashe Elazar
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California 94305, USA
J Virol 77:6055-61. 2003..Moreover, an AH peptide-mimic inhibits the membrane association of NS5A in a dose-dependent manner. These results have exciting implications for the HCV life cycle and novel antiviral strategies... - A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replicationShirit Einav
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305-5187, USA
J Virol 78:11288-95. 2004..Genetically disrupting the NBM impairs GTP binding and hydrolysis and dramatically inhibits HCV RNA replication. These results have exciting implications for the HCV life cycle and novel antiviral strategies... - Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane raftsMeirav Matto
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR Building, Room 3115, 269 Campus Dr, Palo Alto, CA 94305-5187, USA
J Virol 78:12047-53. 2004..These results may have broad implications for the HCV life cycle and suggest that the HCV core may be a valuable probe for host cell biology...
Research Grants
- HCV NS4B: Translating molecular virology into novel antiviral therapiesJeffrey S Glenn; Fiscal Year: 2010....
- HCV NS5A: Molecular Virology and Antiviral TargetJeffrey S Glenn; Fiscal Year: 2010..We will use phage display to identify high affinity random peptide ligands of the AH. Finally, we will explore how our results can be translated into novel anti-HCV strategies. ..